Navigation Links
CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer
Date:3/12/2009

offer commenced by Sturgeon Acquisition, Inc., Astellas US Holding, Inc. and Astellas Pharma Inc., the Company is filing with the Securities and Exchange Commission a Solicitation/Recommendation Statement on Schedule 14D-9. Stockholders of CV Therapeutics are advised to read CV Therapeutics' Schedule 14D-9 statement regarding the Astellas tender offer, because it contains important information. Stockholders may obtain a free copy of the statement at the SEC's website at www.sec.gov. Stockholders may also obtain, without charge, a copy of the statement from MacKenzie Partners, Inc., which is assisting CV Therapeutics, by calling 800-322-2885 toll free or by calling 212-929-5500 or by emailing cvtx@mackenziepartners.com.

This press release contains forward looking statements regarding the future financial and operating results of CV Therapeutics and other statements regarding its intentions, beliefs, expectations, plans, prospects or predictions for the future. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2008. CV Therapeutics disclaims any intent or obligation to
'/>"/>

SOURCE CV Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  An entire month is dedicated ... neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular ... extreme muscle atrophy, weakness, and foot and hand deformities. ... millions worldwide. CMT is a progressive disease, and over ... requiring mobility devices such as leg braces, wheelchairs and ...
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2
... After receiving FDA clearance for two new brain imaging ... to market its products to healthcare providers. , ,Approval ... for Devices and Radiologic Health in June allowed ... products to its line of brain mapping solutions based ...
... Healthcare has received permission to continue trading company stock ... listing standards. , ,Merge, a developer of medical imaging and ... will allow it to continue listing its common stock subject ... 29, 2006. The company was unable to comply with filing ...
... is a world-class company and object of emulation for many. ... true conglomerate, but one that is more than an investment ... from aircraft engines and massive power-generating turbines to financial services ... GE is knowledge intensive in all its businesses and global ...
Cached Biology Technology:Kyron wins FDA approval for brain imaging technology 2Growth through the eyes of GE's Immelt 2Growth through the eyes of GE's Immelt 3Growth through the eyes of GE's Immelt 4Growth through the eyes of GE's Immelt 5
(Date:9/18/2014)... its newborn screening program into a model other states can ... first-ever Newborn Screening Quality Award from the March of Dimes. ... Arizona,s Department of Health Services director, with the award at ... of full transparency for the length of time it takes ... for analysis, and set a target of having 95 percent ...
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... Jerrold Meyer and colleagues at the University of Massachusetts ... as an important new biomarker for stress in wild ... demonstrated in the current issue of the Journal ... lab manager Kendra Rosenberg and neuroscience and behavior graduate ...
... 2014) Researchers from Massachusetts Eye and Ear, ... Massachusetts General Hospital have demonstrated, for the first ... of vestibular schwannomas (also known as acoustic neuromas), ... hearing loss and tinnitus. Motivated by ...
... and why now? , Islands are renowned for their ... biogeography, and ecology. As a result of the devastating ... and island conservation has become a vital international concern. ... islands at an unprecedented pace, and now is an ...
Cached Biology News:Biomarker for stress hormones in polar bears, wildlife affected by global climate change 2Aspirin intake may stop growth of vestibular schwannomas/acoustic neuromas 2Island Biology 2014: An International Conference on Island Evolution, Ecology, and Conservation 2
... Immunogen: KLH-conjugated, synthetic peptide ... which [ Ac K] corresponds to acetyl ... Accession Number: NM_003493 ... Quality Assurance: Routinely ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Naked1 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: